The european medicines agency's committee for medicinal products for human use has recommended five new medicines for approval. These medicines appear to address a range of conditions, including rare diseases and aggressive cancers, such as metastatic triple-negative breast cancer. The specific conditions and patient populations targeted by the recommended medicines include metastatic breast cancer and infant rsv prevention, among others.